Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sucampo Submits NDA For Constipation Agent Lubiprostone

This article was originally published in The Pink Sheet Daily

Executive Summary

Standard review is expected, setting a user fee deadline in January 2006. Sucampo plans to begin Phase III trials in constipation-predominant irritable bowel syndrome “soon.” The oral agent would be marketed by Takeda’s U.S. subsidiary.
Advertisement

Related Content

Takeda/Sucampo To Launch Constipation Agent Amitiza In Early Second Quarter
Takeda/Sucampo To Launch Constipation Agent Amitiza In Early Second Quarter
Novartis' Zelnorm Approved For Chronic Constipation Without Gender Restrictions
Novartis' Zelnorm Approved For Chronic Constipation Without Gender Restrictions

Topics

Advertisement
UsernamePublicRestriction

Register

PS061945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel